JP2020143081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020143081A5 JP2020143081A5 JP2020080282A JP2020080282A JP2020143081A5 JP 2020143081 A5 JP2020143081 A5 JP 2020143081A5 JP 2020080282 A JP2020080282 A JP 2020080282A JP 2020080282 A JP2020080282 A JP 2020080282A JP 2020143081 A5 JP2020143081 A5 JP 2020143081A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- acceptable salt
- pharmaceutically acceptable
- protecting groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- 125000006239 protecting group Chemical group 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 24
- 238000000034 method Methods 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- -1 1-methyl-1H-pyrazole-4-yl Chemical group 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000012351 deprotecting agent Substances 0.000 claims 1
- 230000022244 formylation Effects 0.000 claims 1
- 238000006170 formylation reaction Methods 0.000 claims 1
- 0 *[C@@](CCCC1)[C@@]1N Chemical compound *[C@@](CCCC1)[C@@]1N 0.000 description 20
- BECXWGINFVUKDI-UHFFFAOYSA-N O=C(c1c(nc2F)Cl)NCc1c2F Chemical compound O=C(c1c(nc2F)Cl)NCc1c2F BECXWGINFVUKDI-UHFFFAOYSA-N 0.000 description 3
- UCNGGGYMLHAMJG-UHFFFAOYSA-N CC1(C)OB(c2c[n](C)nc2)OC1(C)C Chemical compound CC1(C)OB(c2c[n](C)nc2)OC1(C)C UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 2
- PBNKENFXRLNYCJ-UHFFFAOYSA-N CC1(C)OS(c2c[n](C)nc2)OC1(C)C Chemical compound CC1(C)OS(c2c[n](C)nc2)OC1(C)C PBNKENFXRLNYCJ-UHFFFAOYSA-N 0.000 description 1
- JBLHYAFLUQSWOF-UHFFFAOYSA-N NC(c(c(Cl)n1)cc(F)c1F)=O Chemical compound NC(c(c(Cl)n1)cc(F)c1F)=O JBLHYAFLUQSWOF-UHFFFAOYSA-N 0.000 description 1
- OJKXBPMNEIRBIC-UHFFFAOYSA-N OC(c(c1c(nc2F)Cl)c2F)NC1=O Chemical compound OC(c(c1c(nc2F)Cl)c2F)NC1=O OJKXBPMNEIRBIC-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021180105A JP2022017477A (ja) | 2014-12-18 | 2021-11-04 | 縮合複素芳香族ピロリジノンの固体状態形態 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462093564P | 2014-12-18 | 2014-12-18 | |
| US62/093,564 | 2014-12-18 | ||
| US201562115223P | 2015-02-12 | 2015-02-12 | |
| US62/115,223 | 2015-02-12 | ||
| US201562180222P | 2015-06-16 | 2015-06-16 | |
| US62/180,222 | 2015-06-16 | ||
| JP2017532678A JP6778195B2 (ja) | 2014-12-18 | 2015-12-17 | 縮合複素芳香族ピロリジノンの固体状態形態 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532678A Division JP6778195B2 (ja) | 2014-12-18 | 2015-12-17 | 縮合複素芳香族ピロリジノンの固体状態形態 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021180105A Division JP2022017477A (ja) | 2014-12-18 | 2021-11-04 | 縮合複素芳香族ピロリジノンの固体状態形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020143081A JP2020143081A (ja) | 2020-09-10 |
| JP2020143081A5 true JP2020143081A5 (https=) | 2020-11-26 |
| JP6974534B2 JP6974534B2 (ja) | 2021-12-01 |
Family
ID=55299676
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532678A Active JP6778195B2 (ja) | 2014-12-18 | 2015-12-17 | 縮合複素芳香族ピロリジノンの固体状態形態 |
| JP2020080282A Active JP6974534B2 (ja) | 2014-12-18 | 2020-04-30 | 縮合複素芳香族ピロリジノンの固体状態形態 |
| JP2021180105A Pending JP2022017477A (ja) | 2014-12-18 | 2021-11-04 | 縮合複素芳香族ピロリジノンの固体状態形態 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532678A Active JP6778195B2 (ja) | 2014-12-18 | 2015-12-17 | 縮合複素芳香族ピロリジノンの固体状態形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021180105A Pending JP2022017477A (ja) | 2014-12-18 | 2021-11-04 | 縮合複素芳香族ピロリジノンの固体状態形態 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10676473B2 (https=) |
| EP (2) | EP3677582B1 (https=) |
| JP (3) | JP6778195B2 (https=) |
| KR (1) | KR102037502B1 (https=) |
| CN (1) | CN107108609B (https=) |
| AU (1) | AU2015365580B2 (https=) |
| BR (1) | BR112017013149B1 (https=) |
| CA (1) | CA2970864C (https=) |
| CL (1) | CL2017001561A1 (https=) |
| CO (1) | CO2017005910A2 (https=) |
| CR (1) | CR20170249A (https=) |
| DK (1) | DK3233857T3 (https=) |
| DO (1) | DOP2017000130A (https=) |
| EA (1) | EA032291B1 (https=) |
| EC (1) | ECSP17038100A (https=) |
| ES (1) | ES2788454T3 (https=) |
| GE (2) | GEP20197050B (https=) |
| IL (1) | IL252941B (https=) |
| MX (1) | MX373586B (https=) |
| MY (1) | MY199935A (https=) |
| NZ (1) | NZ732371A (https=) |
| PE (1) | PE20171179A1 (https=) |
| PH (1) | PH12017501123A1 (https=) |
| PL (1) | PL3233857T3 (https=) |
| SG (1) | SG11201701911QA (https=) |
| TN (1) | TN2017000080A1 (https=) |
| UA (1) | UA120632C2 (https=) |
| WO (1) | WO2016097862A2 (https=) |
| ZA (1) | ZA201701800B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2017000080A1 (en) * | 2014-12-18 | 2018-07-04 | Takeda Pharmaceuticals Co | Solid state forms of fused heteroaromatic pyrrolidinones |
| US20190231757A1 (en) * | 2016-07-13 | 2019-08-01 | Takeda Pharmaceutical Company Limited | Combination of spleen tyrosine kinase inhibitors and other therapeutic agents |
| CN111194319A (zh) | 2017-10-19 | 2020-05-22 | 拜耳动物保健有限责任公司 | 稠合的杂芳族吡咯烷酮类化合物用于治疗和预防动物中的疾病的用途 |
| WO2019088039A1 (en) | 2017-10-30 | 2019-05-09 | Takeda Pharmaceutical Company Limited | Treatment of acute myeloid leukemia |
| WO2020119785A1 (zh) * | 2018-12-14 | 2020-06-18 | 正大天晴药业集团股份有限公司 | 一种Syk抑制剂的盐及其结晶型 |
| BR112021014456A2 (pt) | 2019-02-07 | 2021-09-21 | Janssen Biotech, Inc. | Inibidores de di-hidro-orotato desidrogenase |
| TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| JP2022552496A (ja) | 2019-10-10 | 2022-12-16 | ヤンセン バイオテツク，インコーポレーテツド | ビアリールジヒドロオロト酸デヒドロゲナーゼ阻害剤 |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| WO2022074534A1 (en) | 2020-10-05 | 2022-04-14 | Janssen Biotech, Inc. | Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents |
| WO2022127753A1 (zh) * | 2020-12-18 | 2022-06-23 | 山东轩竹医药科技有限公司 | 稠环类AhR抑制剂 |
| PE20240588A1 (es) | 2021-05-11 | 2024-03-21 | Janssen Pharmaceutica Nv | Terapias de combinacion |
| MX2023013410A (es) | 2021-05-11 | 2023-12-06 | Janssen Pharmaceutica Nv | Terapias de combinacion. |
| KR102539612B1 (ko) | 2021-12-24 | 2023-06-02 | 엘에스일렉트릭(주) | IP 기반 RAPIEnet을 지원하는 통신 디바이스 및 이를 포함하는 네트워크 시스템 |
| WO2024114666A1 (en) | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
| EP4626426A1 (en) | 2022-11-30 | 2025-10-08 | JANSSEN Pharmaceutica NV | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007070872A1 (en) * | 2005-12-15 | 2007-06-21 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
| NZ601267A (en) | 2009-12-23 | 2014-03-28 | Takeda Pharmaceutical | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| EP2723739B1 (en) | 2011-06-22 | 2016-08-24 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| WO2016048982A2 (en) * | 2014-09-24 | 2016-03-31 | Millennium Pharmaceuticals, Inc. | COMBINATION TREATMENT WITH PI3Kα INHIBITORS AND TAXANES |
| TN2017000080A1 (en) * | 2014-12-18 | 2018-07-04 | Takeda Pharmaceuticals Co | Solid state forms of fused heteroaromatic pyrrolidinones |
-
2015
- 2015-12-17 TN TN2017000080A patent/TN2017000080A1/en unknown
- 2015-12-17 US US14/973,180 patent/US10676473B2/en active Active
- 2015-12-17 JP JP2017532678A patent/JP6778195B2/ja active Active
- 2015-12-17 WO PCT/IB2015/002489 patent/WO2016097862A2/en not_active Ceased
- 2015-12-17 CN CN201580068971.2A patent/CN107108609B/zh active Active
- 2015-12-17 AU AU2015365580A patent/AU2015365580B2/en active Active
- 2015-12-17 ES ES15831150T patent/ES2788454T3/es active Active
- 2015-12-17 BR BR112017013149-8A patent/BR112017013149B1/pt not_active IP Right Cessation
- 2015-12-17 NZ NZ732371A patent/NZ732371A/en not_active IP Right Cessation
- 2015-12-17 PL PL15831150T patent/PL3233857T3/pl unknown
- 2015-12-17 PE PE2017000944A patent/PE20171179A1/es unknown
- 2015-12-17 EA EA201791369A patent/EA032291B1/ru unknown
- 2015-12-17 EP EP20156863.1A patent/EP3677582B1/en active Active
- 2015-12-17 CA CA2970864A patent/CA2970864C/en active Active
- 2015-12-17 SG SG11201701911QA patent/SG11201701911QA/en unknown
- 2015-12-17 UA UAA201707489A patent/UA120632C2/uk unknown
- 2015-12-17 GE GEAP201514545A patent/GEP20197050B/en unknown
- 2015-12-17 CR CR20170249A patent/CR20170249A/es unknown
- 2015-12-17 GE GEAP201914545A patent/GEAP201914545A/en unknown
- 2015-12-17 DK DK15831150.6T patent/DK3233857T3/da active
- 2015-12-17 EP EP15831150.6A patent/EP3233857B1/en active Active
- 2015-12-17 MX MX2017007162A patent/MX373586B/es active IP Right Grant
- 2015-12-17 KR KR1020177019929A patent/KR102037502B1/ko active Active
- 2015-12-17 MY MYPI2017702209A patent/MY199935A/en unknown
-
2017
- 2017-03-13 ZA ZA2017/01800A patent/ZA201701800B/en unknown
- 2017-05-31 DO DO2017000130A patent/DOP2017000130A/es unknown
- 2017-06-15 CL CL2017001561A patent/CL2017001561A1/es unknown
- 2017-06-15 PH PH12017501123A patent/PH12017501123A1/en unknown
- 2017-06-15 IL IL252941A patent/IL252941B/en active IP Right Grant
- 2017-06-15 CO CONC2017/0005910A patent/CO2017005910A2/es unknown
- 2017-06-16 EC ECIEPI201738100A patent/ECSP17038100A/es unknown
-
2020
- 2020-04-30 JP JP2020080282A patent/JP6974534B2/ja active Active
- 2020-05-08 US US16/870,653 patent/US11352355B2/en active Active
-
2021
- 2021-11-04 JP JP2021180105A patent/JP2022017477A/ja active Pending
-
2022
- 2022-12-23 US US18/088,286 patent/US20230348461A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020143081A5 (https=) | ||
| JP2022043078A5 (https=) | ||
| TW200848018A (en) | A therapeutic medicine of influenza | |
| WO2017201846A1 (zh) | 一种噁唑烷酮类抗菌药物及其中间体的制备方法 | |
| TWI579259B (zh) | 製備（１ｒ，２ｓ）－２－（３，４－二氟苯基）－３－ｒ取代－環丙胺的方法 | |
| CN103333942A (zh) | 左旋吡喹酮的合成方法 | |
| JP2003525287A5 (ja) | １,３-ジヒドロ-２ｈ-インドール-２-オンならびにアルギニン-バソプレッシンのｖ1bまたはｖ1bおよびｖ1aの両方のレセプターのリガンドとしてのそれらの使用 | |
| JP2025502931A (ja) | 薬物－リンカー複合体の調製方法 | |
| CN113087712B (zh) | L-氨基酸-6-胶霉毒素酯三氟乙酸盐及其制备方法 | |
| TWI746639B (zh) | 小蘗鹼型生物鹼之製造方法 | |
| CN102250101A (zh) | 二-α-喹啉-低聚乙二醇酞菁锌及其制备方法 | |
| JP2022116171A5 (https=) | ||
| JP2018525406A (ja) | アリール化合物の合成 | |
| TWI548615B (zh) | 化合物、及其製造方法 | |
| CN112110897B (zh) | 一种氘代克里唑蒂尼及其衍生物的制备方法 | |
| Bo et al. | In situ solvent and counteranion-induced synthesis, structural characterization and photoluminescence properties of Pb-based MOFs | |
| Yang et al. | A 3D photoluminescent cadmium (II)-organic framework with unusual pentanuclear cluster as secondary building unit | |
| CN114249723B (zh) | 一种唑吡坦及其关键中间体的制备方法 | |
| CN110372533B (zh) | 一种阳离子型线性氯胺抗菌剂及其合成方法 | |
| CN105461662A (zh) | 一种抗hiv药物中间体的手性环氧化合物的合成方法 | |
| Xie et al. | Synthesis of Nitrogen Bridgehead Heterocycles with Phosphonates via a Novel Tandem Process | |
| US9108918B2 (en) | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate | |
| JP2006514071A5 (https=) | ||
| CN107973830B (zh) | 一种新奥霉素的全合成方法 | |
| WO2020234381A1 (en) | Processes and intermediates for preparing a btk inhibitor |